Molecular imprinting of miR-559 on a peptide-immobilized poly L-DOPA/silica core-shell and in vitro investigating its effects on HER2-positive breast cancer cells

Drug Deliv Transl Res. 2023 Oct;13(10):2487-2502. doi: 10.1007/s13346-023-01330-x. Epub 2023 Mar 29.

Abstract

In a significant percentage of breast cancers, increased expression of the HER2 receptor is seen and is associated with the spread and worsening of the disease. This research aims to investigate the effect of miR-559 (which targets HER2 mRNA) on SKBR3 breast cancer cells and the possibility of their effective delivery with polymeric nanoparticles and tumor-targeting peptides. L-DOPA monomers were polymerized on the surface of silica nanoparticles in the presence of miR-559 (as a molecular template for molecular imprinting) then an anti-HER2 peptide coupled to the surface of these polymeric nanocomposites (miR-NC-NL2), and the effects of this construct against a HER2-positive breast cancer cells (SKBR3 cells) investigated in vitro conditions. The results showed that miR-NC-NL2 is selective for HER2-positive cells and delivers the miR-559 to them in a targeted manner. miR-NC-NL2 decreased the proliferation of SKBR3 cells and reduced the expression and production of HER2 protein in these cells. Effective and targeted delivery of miR-559 to HER2-positive cancer cells by the miR-NC-NL2 promises the therapeutic potential of this nascent structure based on its inhibitory effect on cancer growth and progression. Of course, animal experiments require a better understanding of this structure's anti-tumor effects.

Keywords: HER2-positive breast cancer; L-DOPA; MicroRNA-559; Molecular imprinted polymers; Tumor-targeting peptide.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Cell Proliferation
  • Levodopa / pharmacology
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Molecular Imprinting*
  • Neoplasms*
  • Peptide Fragments / pharmacology
  • Receptor, ErbB-2 / genetics
  • Receptor, ErbB-2 / metabolism
  • Silicon Dioxide

Substances

  • Levodopa
  • Silicon Dioxide
  • Receptor, ErbB-2
  • Peptide Fragments
  • MicroRNAs